InterCure Ltd. (NASDAQ:INCR) Sees Large Decrease in Short Interest

InterCure Ltd. (NASDAQ:INCRGet Rating) was the target of a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 27,800 shares, a decline of 44.2% from the March 31st total of 49,800 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 68,200 shares, the days-to-cover ratio is presently 0.4 days.

Shares of INCR traded down $0.38 on Friday, hitting $5.79. The company’s stock had a trading volume of 52,387 shares, compared to its average volume of 15,116. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.74 and a quick ratio of 1.39. The firm’s fifty day moving average price is $6.55 and its 200-day moving average price is $6.82. InterCure has a fifty-two week low of $4.50 and a fifty-two week high of $8.77.

Institutional investors and hedge funds have recently modified their holdings of the stock. Ibex Investors LLC acquired a new position in shares of InterCure in the 3rd quarter valued at approximately $9,397,000. Goldman Sachs Group Inc. acquired a new position in InterCure during the 3rd quarter worth approximately $283,000. Marshall Wace LLP acquired a new position in InterCure during the 3rd quarter worth approximately $776,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in InterCure during the 3rd quarter worth approximately $1,466,000. Finally, Citadel Advisors LLC boosted its position in InterCure by 12.4% during the 4th quarter. Citadel Advisors LLC now owns 31,741 shares of the company’s stock worth $206,000 after acquiring an additional 3,499 shares during the last quarter. Institutional investors and hedge funds own 7.69% of the company’s stock.

About InterCure (Get Rating)

InterCure Ltd, together with its subsidiaries, engages in production of medical cannabis products in Israel and internationally. It also offers pharmaceutical-grade cannabis products. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

See Also

Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.